1. Home
  2. XGN vs LPCN Comparison

XGN vs LPCN Comparison

Compare XGN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$3.06

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$2.02

Market Cap

61.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XGN
LPCN
Founded
2002
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.5M
61.8M
IPO Year
2014
2011

Fundamental Metrics

Financial Performance
Metric
XGN
LPCN
Price
$3.06
$2.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
1
Target Price
$9.14
$15.00
AVG Volume (30 Days)
289.2K
100.9K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
N/A
$1,976,677.00
Revenue This Year
$8.06
N/A
Revenue Next Year
$12.93
$74.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.59
$2.52
52 Week High
$12.23
$12.37

Technical Indicators

Market Signals
Indicator
XGN
LPCN
Relative Strength Index (RSI) 46.86 25.40
Support Level N/A N/A
Resistance Level $3.79 $3.42
Average True Range (ATR) 0.21 0.59
MACD 0.05 -0.23
Stochastic Oscillator 67.14 2.98

Price Performance

Historical Comparison
XGN
LPCN

About XGN Exagen Inc.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: